Synthesis and in vitro evaluation of 99mTc radiolabeled lapatinib (LPT) and its PLGA formulation-Reference-Cited by-同舟云学术

Synthesis and in vitro evaluation of 99mTc radiolabeled lapatinib (LPT) and its PLGA formulation

Published:2024-01-19 Issue:2 Volume:333 Page:665-672
ISSN:0236-5731
Container-title:Journal of Radioanalytical and Nuclear Chemistry
language:en
Short-container-title:J Radioanal Nucl Chem

Author:

Gokulu Sevki Goksun^ORCID,Karatay Kadriye Busra^ORCID,Bilgi Ahmet^ORCID,Kayas Cansu^ORCID,Yildirim Nuri^ORCID,Kilcar Ayfer Yurt^ORCID,Muftuler Fazilet Zumrut Biber^ORCID,Terek Mustafa Cosan^ORCID,Akman Levent^ORCID

Funder

Ege University Research Foundation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10967-023-09292-7.pdf

Reference25 articles.

1. Mukama T, Kharazmi E, Xu X, Sundquist K, Sundquist J, Brenner H et al (2020) Risk-adapted starting age of screening for relatives of patients with breast cancer. JAMA Oncol 6(1):68–74. https://doi.org/10.1001/jamaoncol.2019.3876

2. Wu P, Zhu Y, Liu S, Xiong H (2021) Modular design of high-brightness pH-activatable near-infrared BODIPY probes for noninvasive fluorescence detection of deep-seated early breast cancer bone metastasis: remarkable axial substituent effect on performance. ACS Cent Sci 7(12):2039–2048. https://doi.org/10.1021/acscentsci.1c01066

3. Xia W, Gerard CM, Liu L et al (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:6213–6221. https://doi.org/10.1038/SJ.ONC.1208774

4. Liu H, Ruan S, Larsen ME et al (2023) Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo. Biol Proced Online 25:19. https://doi.org/10.1186/s12575-023-00212-3

5. Moreira C, Kaklamani V (2010) Lapatinib and breast cancer: current indications and outlook for the future. Expert Rev Antican Therapy 10:1171–1182. https://doi.org/10.1586/ERA.10.113